Evidence map›Paper›PMID 40354193›Full record

ArticleAging cell2025

dVGLUT Is a Mediator of Sex Differences in Dopamine Neuron Mitochondrial Function Across Aging and in a Parkinson's Disease Model.

Silas A Buck, Samuel J Mabry, Tenzin Kunkhyen, Zilu Yang, Sophie A Rubin, Jinting Yang, Claire E J Cheetham, Zachary Freyberg

Abstract read
In one paragraph

Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. VGLUT2 in Parkinson's disease: an emerging therapeutic target.Expert opinion on therapeutic targets · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silas A BuckCenter for Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Samuel J MabryDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Tenzin KunkhyenDepartment of Neurobiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Zilu YangDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0009-0007-1140-769X
Sophie A RubinDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Jinting YangDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Claire E J CheethamDepartment of Neurobiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Zachary FreybergDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-6460-0118

Funding

CLINICAL RESEARCH TRAINING IN LATE-LIFE MOOD DISORDERST32MH019986 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOWARD J AIZENSTEIN, Carmen Andreescu · 1997 to 2026
$6.9M
Novel roles of VGLUT in sex differences in dopamine neuron vulnerability to environmental toxicant-induced neurodegenerationR01ES034037 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZACHARY FREYBERG · 2023 to 2026
$2.3M
Novel roles for the circadian transcription factor NPAS2 and striatal dopamine D3 receptor signaling in diurnal fentanyl craving and relapseR01DA061243 · NIDA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ZACHARY FREYBERG, Ryan W Logan · 2024 to 2026
$1.4M
A novel role for midbrain glutamate co-transmitting neurons in alcohol drinking and motivated behaviorsR21AA028800 · NIAAA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FREYBERG, ZACHARY, LOGAN, RYAN W · 2021 to 2022
$446k
Mechanisms for Preserving Neurons in Alzheimer's Disease-Related Dementias Across Drosophila and Mouse ModelsR21AG068607 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FREYBERG, ZACHARY · 2020 to 2021
$430k
Dopamine Neuron VGLUT2 Expression in Parkinson's DiseaseF31NS118811 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUCK, SILAS · 2021 to 2023
$124k
Commonwealth of Pennsylvania PA-HEALTHNIAAA NIH HHS R21 AA028800NIAAA NIH HHS R21AA028800NIA NIH HHS R21 AG068607NIA NIH HHS R21AG068607NIDA NIH HHS R01 DA061243NIDA NIH HHS R01DA061243NIEHS NIH HHS 3R01ES034037-02A1NIEHS NIH HHS R01 ES034037NIEHS NIH HHS R01ES034037NIMH NIH HHS T32 MH019986NIMH NIH HHS T32MH019986NINDS NIH HHS F31 NS118811NINDS NIH HHS F31NS118811Pittsburgh Foundation FPG00043
6 · The paper itself

Abstract

Sex differences in Parkinson's disease (PD) offer insights into mechanisms of dopaminergic cell resilience. Female dopamine (DA) neurons are more resilient via mechanisms that remain unclear. Here, we discovered key sex and regional differences in mitochondrial generation of cytotoxic reactive oxygen species (ROS) and their implications for DA neuron resilience using the Drosophila model. While aging raised mitochondrial ROS in DA neurons of both sexes, we observed a sexually dimorphic response in the paraquat (PQ) PD model. DA neuron knockdown of the Drosophila vesicular glutamate transporter (dVGLUT) increased mitochondrial ROS only in males, leaving females protected. Cell depolarization, a physiological stressor, similarly raised mitochondrial ROS in DA neurons selectively in males following dVGLUT knockdown. We also identified dVGLUT-dependent changes in intracellular ATP in both sexes. Overall, we discovered sexually dimorphic relationships between dVGLUT, ATP synthesis, and ROS generation in DA neurons, providing a mechanistic basis for DA neuron resilience.

Indexed as

AgingDopaminergic NeuronsDrosophila ProteinsMitochondriaParkinson DiseaseSex CharacteristicsAdenosine TriphosphateAnimalsDisease Models, AnimalDrosophila melanogasterFemaleMaleReactive Oxygen SpeciesAdenosine TriphosphateDrosophila ProteinsReactive Oxygen SpeciesagingdopamineDrosophiladVGLUTglutamatemitochondriaParkinson's diseasereactive oxygen species

Identifiers

PMID40354193
PMCPMC12341811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.